Mechanism of action of hydroxychloroquine as an antirheumatic drug

Seminars in Arthritis and Rheumatism

Volumn 23, Issue 2, 1993, Pages 82-91

  Fox, Robert I ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

arthritis; Chloroquine; hydroxychloroquine; lupus

Indexed keywords

ANTI INFLAMMATORY AGENTS, NON STEROIDAL; ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; AUTOANTIGEN; CD4 ANTIGEN; GLUCOCORTICOID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ACUTE PHASE PROTEIN; ANTIMETABOLITE; ANTIRHEUMATIC AGENT; ARACHIDONIC ACID; ASIALOGLYCOPROTEIN; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CYTOKINE; FIBRINOGEN; FIBRONECTIN; GROWTH HORMONE; HEME; HEMOGLOBIN; HYDROLASE; ICOSANOID; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; MEPACRINE; PHOSPHOLIPASE A2; PROTEIN; UNINDEXED DRUG;

ARTICLE; AUTOIMMUNITY; DRUG EFFECT; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; PH; T LYMPHOCYTE; ANTIGEN PRESENTATION; CELL PH; DOSE CALCULATION; DRUG DISPOSITION; DRUG MECHANISM; HELPER CELL; MALARIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANTIGEN PRESENTING CELL; ANTIMALARIAL ACTIVITY; BLOOD TOXICITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; ERYTHROCYTE SEDIMENTATION RATE; ETIOLOGY; EYE TOXICITY; IMMUNE RESPONSE; MACROPHAGE; MODEL; NONHUMAN; PAIN; PHOTOSENSITIVITY DISORDER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; AUTOIMMUNITY; CHLOROQUINE; HUMAN; HYDROGEN-ION CONCENTRATION; HYDROXYCHLOROQUINE; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDES; T-LYMPHOCYTES;

EID: 0027434905     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(10)80012-5     Document Type: Article

References (48)

1. Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials
2. Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid releases by human blood monocytes
3. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers
4. Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients
5. Metabolic basis of diethylami-noethoxy-hexestrol-induced phospholipid fatty liver
6. Chloroquine serum concentration and side effects: Evidence for dose-dependent kinetics
7. Lysosomes, pH and the antimalarial action of chloroquine
8. Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum.
9. A perspective on antimalarial actions: Effects of weak bases on Plasmodium falciparum
10. Efflux of chloroquine from Plasmodium falciparum: Mechanism of chloroquine resistance
11. Inhibition by chloroquine of a novel heme polymerase enzyme activity in malaria trophozoites
12. Acidification of the endocytic and exocytic pathways
13. Receptor-mediated endocytosis
14. Chloroquine and ammonium ion inhibit receptor-mediated endocytosis of man-nose-glycoconjugates by macrophages: Apparent inhibition of receptor recycling
15. Recycling of the asialoglycoprotein receptor and the effect of lysosomotropic amines in hepatoma cells
16. Receptor-mediated endocytosis of hormones in cultured cells
17. Inhibition of human immunodeficiency virus infectivity by chloroquine
18. Co-localization of molecules involved in antigen processing and presentation in an early endocytic compartment
19. Subunit of the ‘20S’ proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex
20. Second proteasome-related gene in the human MHC class II region
21. Antigen-presenting function of the macrophage
22. Class II MHC molecules can use the endogenous pathway of antigen presentation
23. Autoimmune diseases: The failure of self tolerance
24. Control of granulocytes and macrophages: Molecular, cellular, and clinical aspects
25. Regulation of antigen presentation by acidic pH
26. How MHC class II molecules work: Peptide-dependent completion of protein folding
27. Membrane insertion and oligomeric assembly of HLA-DR histocompatibility antigens
28. Intracellular transport of class II MHC molecules directed by invariant chain
29. The invariant dating service
30. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways
31. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding
32. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules
33. Antigen processing and presentation to T cells
34. A comparison of the stimulatory activities of lymphoid dendritic cells and macrophages in T cell proliferative responses to various antigens
35. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells
36. Chloroquine affects biosynthesis of la molecules by inhibiting dissociation of invariant (7) chains from α-β dimers in B cells
37. The human class II MHC protein HLA-DR 1 assembles as empty α-β heterodimers in the absence of antigenic peptide
38. Distinction between immunogenicity and tolerogenicity among HBcAg T cell determinants
39. Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T cell peptide and inhibited with non-self peptides
40. The role of the T cell receptor in positive and negative selection of developing T cells
41. Immunosuppressive potential of antimalarials
42. Chloroquine treatment in rheumatoid arthritis
43. Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro
44. Studies on drug-induced lipidosis: Subcellular localization of phospholipid and cholesterol in the liver of rats treated with chloroquine or 4,4'-bis(diethylaminoethoxy) α,β-diethyldiphenylethane
45. Chloroquine-induced phospholipid fatty liver
46. Fibronectin and macrophages as parameters of disease-modifying antirheumatic activity
47. Antioxidant action of antimalarials
48. The molecular basis of the action of chloroquine in porphyria cutanea tarda